Department of Dermatology

Autoimmune Skin Disease Study Unit

Lupus Erythematosus

  • A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of CC-220 in Subjects with Active Systemic Lupus
  • A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects with Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects with Active Cutaneous Lupus Erythematosus with or without Systemic Manifestations
  • A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Filgotinib and GS-9876 in Female Subjects with Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)
  • Optimization of Clinical Trial Design in Cutaneous Lupus: NIH funded study to collect data on natural disease activity and outcomes

Dermatomyositis

  • A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis
  • A Phase 2A, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of PF-06823859 in Adult Subjects with Dermatomyositis

Pemphigus Vulgaris

  • A Phase 1b/2, Multicenter, Open-Label, Safety, and Dose Finding Study of Synt001 in Subjects with Pemphigus (Vulgaris or Foliaceus)
    (Looking for: Patients with pemphigus vulgaris or foliaceus with active skin lesions for >2 weeks who have not received rituximab in the past year.)

To refer a patient or to learn more about the program and participation in a clinical trial, contact us at 215-615-2940. Pharmaceutical and other clinical and research professionals may contact Dr. Victoria Werth directly at werth@pennmedicine.upenn.edu.

Share This Page: